These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 34468898)

  • 21. Elucidation of marine fungi derived anthraquinones as mycobacterial mycolic acid synthesis inhibitors: an in silico approach.
    Sharma A; Islam MH; Fatima N; Upadhyay TK; Khan MKA; Dwivedi UN; Sharma R
    Mol Biol Rep; 2019 Apr; 46(2):1715-1725. PubMed ID: 30715689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In silico Screening of Food and Drug Administration-approved Compounds against Trehalose 2-sulfotransferase (Rv0295c) in Mycobacterium tuberculosis: Insights from Molecular Docking and Dynamics Simulations.
    Sharma D; Gautam S; Srivastava N; Bisht D
    Int J Mycobacteriol; 2024 Jan; 13(1):73-82. PubMed ID: 38771283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repurposing Immunomodulatory Drugs to Combat Tuberculosis.
    Fatima S; Bhaskar A; Dwivedi VP
    Front Immunol; 2021; 12():645485. PubMed ID: 33927718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Revitalizing antimicrobial strategies: paromomycin and dicoumarol repurposed as potent inhibitors of M.tb's replication machinery via targeting the vital protein DnaN.
    Ali W; Agarwal M; Jamal S; Gangwar R; Sharma R; Mubarak MM; Wani ZA; Ahmad Z; Khan A; Sheikh JA; Grover A; Bhaskar A; Dwivedi VP; Grover S
    Int J Biol Macromol; 2024 Oct; 278(Pt 3):134652. PubMed ID: 39173789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-based drug repurposing to inhibit the DNA gyrase of Mycobacterium tuberculosis.
    Gl B; Rajput R; Gupta M; Dahiya P; Thakur JK; Bhatnagar R; Grover A
    Biochem J; 2020 Nov; 477(21):4167-4190. PubMed ID: 33030198
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In Silico Drug Repurposing Approach: Investigation of
    Ngidi NTP; Machaba KE; Mhlongo NN
    Molecules; 2022 Jan; 27(3):. PubMed ID: 35163931
    [No Abstract]   [Full Text] [Related]  

  • 27. Small organic molecules targeting the energy metabolism of Mycobacterium tuberculosis.
    Urban M; Šlachtová V; Brulíková L
    Eur J Med Chem; 2021 Feb; 212():113139. PubMed ID: 33422979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.
    Pieroni M; Wan B; Cho S; Franzblau SG; Costantino G
    Eur J Med Chem; 2014 Jan; 72():26-34. PubMed ID: 24333612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peptidyl-prolyl isomerase-B is involved in
    Kumar A; Alam A; Grover S; Pandey S; Tripathi D; Kumari M; Rani M; Singh A; Akhter Y; Ehtesham NZ; Hasnain SE
    NPJ Biofilms Microbiomes; 2019; 5(1):3. PubMed ID: 30675370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
    Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
    Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel pyrazine based anti-tubercular agents: Design, synthesis, biological evaluation and in silico studies.
    Hassan NW; Saudi MN; Abdel-Ghany YS; Ismail A; Elzahhar PA; Sriram D; Nassra R; Abdel-Aziz MM; El-Hawash SA
    Bioorg Chem; 2020 Mar; 96():103610. PubMed ID: 32028062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In silico Design and Synthesis of Tetrahydropyrimidinones and Tetrahydropyrimidinethiones as Potential Thymidylate Kinase Inhibitors Exerting Anti-TB Activity Against
    Venugopala KN; Tratrat C; Pillay M; Chandrashekharappa S; Al-Attraqchi OHA; Aldhubiab BE; Attimarad M; Alwassil OI; Nair AB; Sreeharsha N; Venugopala R; Morsy MA; Haroun M; Kumalo HM; Odhav B; Mlisana K
    Drug Des Devel Ther; 2020; 14():1027-1039. PubMed ID: 32214795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug re-engineering and repurposing: A significant and rapid approach to tuberculosis drug discovery.
    Reddy DS; Sinha A; Kumar A; Saini VK
    Arch Pharm (Weinheim); 2022 Nov; 355(11):e2200214. PubMed ID: 35841594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mycobacterial Targets for Thiourea Derivatives: Opportunities for Virtual Screening in Tuberculosis Drug Discovery.
    de Melo Milani V; Silva ML; Camargo PG; de Lima Ferreira Bispo M
    Curr Med Chem; 2024; 31(29):4703-4724. PubMed ID: 38375848
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of new benzamide inhibitor against α-subunit of tryptophan synthase from Mycobacterium tuberculosis through structure-based virtual screening, anti-tuberculosis activity and molecular dynamics simulations.
    Naz S; Farooq U; Ali S; Sarwar R; Khan S; Abagyan R
    J Biomol Struct Dyn; 2019 Mar; 37(4):1043-1053. PubMed ID: 29502488
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Angrish N; Lalwani N; Khare G
    Microbiol Spectr; 2023 Dec; 11(6):e0135923. PubMed ID: 37855602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimycobacterial activity of acetone extract and isolated metabolites from folklore medicinal lichen Usnea laevis Nyl. against drug-sensitive and multidrug-resistant tuberculosis strains.
    Tatipamula VB; Annam SSP
    J Ethnopharmacol; 2022 Jan; 282():114641. PubMed ID: 34536516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Mycobacterium tuberculosis drugome and its polypharmacological implications.
    Kinnings SL; Xie L; Fung KH; Jackson RM; Xie L; Bourne PE
    PLoS Comput Biol; 2010 Nov; 6(11):e1000976. PubMed ID: 21079673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Repurposing-a ray of hope in tackling extensively drug resistance in tuberculosis.
    Maitra A; Bates S; Kolvekar T; Devarajan PV; Guzman JD; Bhakta S
    Int J Infect Dis; 2015 Mar; 32():50-5. PubMed ID: 25809756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efflux pump inhibitors as a promising adjunct therapy against drug resistant tuberculosis: a new strategy to revisit mycobacterial targets and repurpose old drugs.
    Rodrigues L; Cravo P; Viveiros M
    Expert Rev Anti Infect Ther; 2020 Aug; 18(8):741-757. PubMed ID: 32434397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.